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Cigarette smoking during pregnancy is associated with numer-
ous obstetrical, fetal, and developmental complications, as well as
an increased risk of adverse health consequences in the adult
offspring. Nicotine replacement therapy (NRT) has been developed
as a pharmacotherapy for smoking cessation and is considered to
be a safer alternative for women to smoking during pregnancy. The
safety of NRT use during pregnancy has been evaluated in
a limited number of short-term human trials, but there is currently
no information on the long-term effects of developmental nicotine
exposure in humans. However, animal studies suggest that nicotine
alone may be a key chemical responsible for many of the long-term
effects associated with maternal cigarette smoking on the
offspring, such as impaired fertility, type 2 diabetes, obesity,
hypertension, neurobehavioral defects, and respiratory dysfunc-
tion. This review will examine the long-term effects of fetal and
neonatal nicotine exposure on postnatal health.
Key Words: nicotine; pregnancy; fetal programming of adult
disease; smoking cessation.
It has been well documented that cigarette smoking during
pregnancy is associated with a number of adverse obstetrical
outcomes including: spontaneous abortion (George et al., 2006),
placenta previa (Chelmow et al., 1996; Faiz and Ananth, 2003;
Hung et al., 2007), placental abruption (Ananth et al., 1999),
preterm birth (Fantuzzi et al., 2007; Kolas et al., 2000), stillbirth
(HogbergandCnattingius,2007;Wisborgetal.,2001),fetalgrowth
restriction (Hammoud et al., 2005; Nordentoft et al., 1996), low
birthweight(Bernsteinetal.,2005;Jaddoeetal.,2008),andsudden
infant death syndrome (SIDS) (Mitchell and Milerad, 2006).
Smokingcessationoratleastreductionofcigarettesmokingduring
pregnancy can ameliorate damage to the developing fetus (Lindley
et al., 2000; Pickett et al., 2003). Indeed, smoking cessation
programs based on behavioral therapy, which are implemented
during pregnancy, have been shown to reduce the incidence of low
birth weight and preterm birth (Lumley et al., 2004).
Although cigarette smoking during pregnancy is associated
with adverse fetal, obstetrical, and developmental outcomes,
15–20% of all women smoke throughout the duration of
pregnancy (Andres and Day, 2000; Bergmann et al., 2003),
despite intentions to refrain from smoking during that period
(Okuyemi et al., 2000). Approximately 75% of pregnant
smokers report the desire to quit smoking (Ruggiero et al.,
2000), but only 20–30% successfully abstain from smoking
during pregnancy and half of these women relapse within
6m o n t h so fp a r t u r i t i o n( Ebert and Fahy, 2007). Smoking
cessation is most effective if implemented before pregnancy or
prior to the initiation of prenatal care (Tong et al.,2 0 0 8 ). For
most women, nicotine dependence is a signiﬁcant element of
their smoking behavior (Okuyemi et al., 2000), and the highly
addictive nature of nicotine makes smoking cessation difﬁcult.
Indeed, the majority of adverse physiological symptoms
associated with smoking cessation (cravings, irritability, rest-
lessness, anxiety, and increased appetite) have been attributed to
nicotine withdrawal (Glynn et al.,2 0 0 9 ). Therefore, nicotine
replacement therapy (NRT) has been widely developed as
a pharmacotherapy of smoking cessation and is considered to be
of beneﬁt for pregnant women who are highly dependent and
have been unable to quit smoking by other means (Benowitz
and Dempsey, 2004; Okuyemi et al.,2 0 0 0 ; Ontario Medical
Association [OMA], 2008; Peters and Morgan, 2002).
In pregnant women who smoke or use NRT, nicotine crosses
the placenta, concentrates in fetal blood and amniotic ﬂuid, and
is detectable in breast milk during lactation (Jordanov, 1990;
Lambers and Clark, 1996; Luck and Nau, 1987). Indeed,
during the ﬁrst week of life, urinary cotinine levels in infants of
smoking mothers who are exclusively breast-fed are signiﬁ-
cantly higher than those who are only bottle fed (fully breast-
fed median 801 ng cotinine/mg creatinine [range 325–1693] vs.
fully bottle fed median 65 ng cotinine/mg creatinine [range 28–
101]; Schwartz-Bickenbach et al., 1987). Therefore, maternal
NRT use results in both fetal and neonatal exposure to nicotine.
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classiﬁed as a Pregnancy Category C drug, whereas the
transdermal nicotine patch is classiﬁed in pregnancy as
Category D (Benowitz and Dempsey, 2004; Pauly and Slotkin,
2008). Based on these U.S. Food and Drug Administration
classiﬁcations, it is generally agreed that the risk to the fetus of
continued smoking outweighs any potential adverse effects of
NRT (Glynn et al., 2009; OMA, 2008). Furthermore, NRT is
thought of as a safer alternative to smoking during pregnancy
because the mother and fetus are exposed to one chemical
instead of the thousands of chemicals found in cigarette smoke
(Glynn et al., 2009; OMA, 2008). It has also been argued that
because NRT usually delivers a dose of nicotine that is
equivalent to smoking 10 cigarettes a day, the fetus will be
exposed to much less nicotine than children born to women
who smoke heavily during pregnancy (Oncken and Kranzler,
2003). The OMA currently recommends that NRT should be
made available to pregnant women who are unable to quit
smoking using nonpharmacologic means (OMA, 2008). In
addition, the Committee on Safety of Medicines (CSM) and
Medicines and Healthcare Regulatory Authority (MHRA) in
the United Kingdom recently changed their policy to
recommend NRT to pregnant and breastfeeding mothers,
stating that although there is a theoretical risk that nicotine
could cause harmful effects, in practice, none have been found
to date (Action on Smoking and Health, 2005). However, there
are several issues with the OMA and CSM/MHRA recom-
mendations. First, NRT use compared with placebo does not
appear to increase the probability of successful smoking
cessation during pregnancy. Although NRT is highly effective
for smoking cessation in non–pregnant smokers (reviewed in
Glynn et al., 2009), there is currently no evidence to suggest
that NRT use is effective for smoking cessation in pregnant
women (assessed by meta-analysis in Lumley et al., 2004).
These ﬁndings may be attributed to the increased rate of
nicotine metabolism in pregnant versus non–pregnant smokers
(60% higher nicotine clearance and 140% higher cotinine
clearance during pregnancy; Dempsey et al., 2002) or may
relate to the low adherence to NRT among pregnant smokers
(Fish et al., 2009). Despite the lack of evidence to support the
efﬁcacy of NRT use during pregnancy, the percentage of
pregnancies in which NRT was prescribed has increased
steadily between 1998 and 2004 (Coleman, 2008). Second,
nicotine may not be the ‘‘safe’’ chemical in cigarettes as was
previously assumed. Notably, in their recently updated smoking
cessation document, the OMA has acknowledged that there is
no safe dose of nicotine during pregnancy (OMA, 2008).
Ginzel et al. (2007) have recently raised concerns about
NRT use during pregnancy, based on evidence of fetotoxicity
and neuroteratogenicity associated with maternal nicotine
exposure. Moreover, maternal smoking is associated with
numerous adverse cardiovascular, respiratory, endocrine, and
metabolic outcomes in the offspring (Beratis et al., 1996;
Bergmann et al., 2003; Blake et al., 2000; Jensen et al., 1998;
Lannero et al., 2006; Montgomery and Ekbom, 2002; Oken
et al., 2008; Power and Jefferis, 2002; Sharpe and Franks,
2002; Syme et al., 2009; Toschke et al., 2002; Weinberg et al.,
1989; Wideroe et al., 2003), yet the effects of nicotine
exposure alone on these outcomes have not been comprehen-
sively evaluated. To date, reviews that evaluate the safety of
NRT use during pregnancy generally consider the acute risks of
nicotine exposure on the developing fetus and, in some cases,
the long-term neurological effects. The goal of this review is to
assess the current evidence regarding the long-term effects of
fetal and neonatal nicotine exposure, an area of research that
has been overlooked in the safety assessment of NRT use
during pregnancy. We will also consider the potential
contribution of nicotine to the long-term toxicity associated
with cigarette smoke exposure during fetal and neonatal
development.
NRT USE DURING PREGNANCY: HUMAN TRIALS
There are an extremely limited number of trials examining
the safety of NRT in humans, all of which focus on obstetrical
outcomes and the short-term toxicological effects on the fetus.
A report by Morales-Suarez-Varela et al. (2006) showed an
increased prevalence of speciﬁc malformations in pregnant
NRT users compared with both nonsmokers and smokers,
whereas Strandberg-Larsen et al. (2008) showed in the same
cohort (Danish National Birth Cohort) that NRT use during
pregnancy was not associated with an increased risk of
stillbirth. A recent, open-label randomized trial by Pollak
et al. (2007), comparing cognitive-behavioral therapy (CBT)
with or without NRT, was the ﬁrst large trial to demonstrate
efﬁcacy of NRT for smoking cessation during pregnancy (but
not postpartum). Unfortunately, this trial was stopped early
because of increased incidence of ‘‘serious adverse events’’ in
the CBT þ NRT group compared with the CBT arm; however,
because of the open-label design of this trial and other
confounding factors, it is difﬁcult to make conclusions about
these data (Pollak et al., 2007). Nicotine gum and patches have
been shown to increase maternal blood pressure and heart rate,
as well as fetal heart rate, but to a lesser degree than cigarette
smoking (reviewed in Dempsey and Benowitz, 2001).
Although smoking is clearly associated with intrauterine
growth restriction (Kolas et al., 2000; Williams et al., 1997),
the role of nicotine in causing this effect is unclear. Two
randomized control trials have found that birth weights were
signiﬁcantly higher in women using nicotine gum (Oncken
et al., 2008) or nicotine patch (Wisborg et al., 2000) compared
with smokers receiving placebo controls. Notably, in both of
these studies, serum cotinine levels were actually lower in the
NRT group than the placebo group (Oncken et al., 2008;
Wisborg et al., 2000). Furthermore, both the NRT and placebo
groups included women who quit smoking, those who reduced
cigarette consumption, and those who did not change smoking
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birth weight in these studies difﬁcult to interpret (Oncken et al.,
2008;Wisborgetal.,2000).Conversely,datafromthe2004Phase
V Pregnancy Risk Assessment Monitoring System indicated that
self-reported NRT use during pregnancy was associated with
a 2-fold increased risk of low birth weight compared with
nonsmokers, whereas a 1.3-fold increased risk was observed in
smokers versusnonsmokers(Gaither etal.,2 0 0 9 ).Therefore, itis
difﬁculttoascertainthe roleofnicotineinthe increasedincidence
of low birth weight associated with maternal smoking because
nicotine exposure in humans may actually be lower in women
using NRT. Results from the ongoing smoking, nicotine and
pregnancy trial, a double-blind placebo-randomized control trial
of NRT in pregnancy (Coleman, 2007), which is expected to end
in 2012, should help to clarify the effects of NRT use during
pregnancy on birth weight.
Currently, there are no prospective epidemiological studies
that examine NRT use during pregnancy and the incidence of
adult-onset disease in the offspring. However, considerable
insight into the long-term effects of developmental nicotine
exposure can be gained from animal models. The general
consensus among clinicians is that more information is needed
about the risks of NRT use during pregnancy before well-
informed deﬁnitive recommendations can be made to pregnant
women (Crawford et al., 2008; Herbert et al., 2005; Lumley
et al., 2009; Oncken and Kranzler, 2009; Osadchy et al., 2009).
Although we agree that there is limited information available
from human trials with NRT during pregnancy, there is
substantial evidence in animal models that can contribute to
dialogue on this subject. Therefore, this review will evaluate
a broader spectrum of outcomes than has been previously
examined, including the long-term consequences of fetal and
neonatal nicotine exposure in animal studies and the potential
contribution of nicotine to the increased incidence of adult-
onset diseases in humans following maternal smoking during
pregnancy.
LONG-TERM EFFECTS OF FETAL AND NEONATAL
EXPOSURE TO NICOTINE
Neurobehavioral Outcomes
The long-term consequences of fetal and neonatal exposure
to nicotine on the central nervous system have been extensively
studied in numerous animal models and are reviewed in detail
elsewhere (reviewed in Dwyer et al., 2009; Pauly and Slotkin,
2008; Winzer-Serhan, 2008). Brieﬂy, nicotine has been clearly
established as a neuroteratogen that compromises the de-
velopment of critical neural pathways in the developing brain
(Dwyer et al., 2009; Pauly and Slotkin, 2008; Winzer-Serhan,
2008). Numerous long-term neurological effects have also been
documented following prenatal nicotine exposure, which are
thought to explain many of the adverse neurobehavioral
outcomes in the offspring of women who smoke during
pregnancy. For instance, epidemiological studies have demon-
strated that prenatal tobacco exposure is associated with
numerous adverse postnatal neurobehavioral outcomes, such
as attention-deﬁcit hyperactivity disorder, learning disabilities,
behavioral problems, and increased risk of nicotine addiction
(reviewed in Cornelius and Day, 2009; Dwyer et al., 2009;
Pauly and Slotkin, 2008; Rogers, 2009; Winzer-Serhan, 2008).
Similarly, prenatal nicotine exposure in rodents causes post-
natal hyperactivity, cognitive impairment, increased anxiety,
somatosensory deﬁcits, persistent neurochemical alterations,
changes in sensitivity to nicotine, alterations in nicotine self-
administration and altered patterns of neural cell survival, and
synaptogenesis (reviewed in Dwyer et al., 2009; Pauly and
Slotkin, 2008; Winzer-Serhan, 2008). Evidence from animal
studies strongly points to nicotine as a key chemical involved
in mediating the long-term neurological effects of develop-
mental cigarette smoke exposure.
Metabolic Outcomes
Because it is well established that maternal cigarette
smoking results in intrauterine growth restriction (Andres and
Day, 2000; England et al., 2001; Robinson et al., 2000;
Wideroe et al., 2003) and that low birth weight is a signiﬁcant
risk factor for the development of obesity, hypertension, and
type 2 diabetes (Barker, 1998; Barker and Clark, 1997;
Godfrey and Barker, 2000, 2001; Ong and Dunger, 2002;
Seckl, 2001), it has been suggested that the association of
cigarette smoking with an increased risk of adverse postnatal
health outcomes is simply a reﬂection of intrauterine growth
restriction. However, maternal smoking increases the risk of
adult-onset diseases in the offspring even after adjustment for
a wide range of confounding factors including birth weight,
socioeconomic status, and maternal diet (Power and Jefferis,
2002; Syme et al., 2009; Von et al., 2002; Wideroe et al.,
2003), suggesting that it may be a direct effect of intrauterine
exposure to the chemicals in cigarette smoke that accounts for
the increased risk of adverse health outcomes in the offspring
of women who smoke during pregnancy. Indeed, recent
epidemiological studies have shown a strong relationship
between maternal smoking and subsequent obesity, hyperten-
sion, and type 2 diabetes in the offspring (Bergmann et al.,
2003; Montgomery and Ekbom, 2002; Oken et al., 2008;
Power and Jefferis, 2002; Syme et al., 2009; Toschke et al.,
2002; Wideroe et al., 2003). Of the 4000 chemicals in cigarette
smoke, animal studies suggest that fetal exposure to nicotine
alone may result in postnatal metabolic alterations associated
with obesity, type 2 diabetes, and hypertension. This
hypothesis is supported by work from our laboratory, which
demonstrated that maternal nicotine exposure during preg-
nancy and lactation in rats results in increased adiposity and/or
increased body weight (Gao et al., 2005; Holloway et al.,
2005), altered perivascular adipose tissue composition and
function (Gao et al., 2008), elevated blood pressure (Gao et al.,
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2005) postnatally. In our animal model, female rats are injected
daily with either nicotine bitartrate (1.0 mg/kg/day) or saline
(vehicle) for 2 weeks prior to mating, 3 weeks during gestation
(fetal development), and 3 weeks during lactation (neonatal
development). The dose of nicotine used in our animal model
results in maternal serum cotinine concentrations of 136 ng/ml
(Holloway et al., 2006), which is within the range of cotinine
levels reported in women who are considered ‘‘moderate
smokers’’ (80–163 ng/ml) (Eskenazi and Bergmann, 1995). In
addition, this dose of nicotine results in serum cotinine
concentrations of 26 ng/ml in the nicotine-exposed offspring
at birth (Holloway et al., 2006), which is also within the range
(5–30 ng/ml) observed in infants nursed by smoking mothers
(Luck and Nau, 1985). The following sections will evaluate
ﬁndings from our animal model as well as similar models of
developmental nicotine exposure by others in the ﬁeld.
Obesity. Prenatal nicotine exposure in rats has been shown
to result in increased postnatal body weight (Gao et al., 2005;
Newman et al., 1999; Somm et al., 2008) and higher levels of
body fat in the fetus at gestational day 20 (Williams and
Kanagasabai, 1984) and offspring during adulthood (Gao et al.,
2005; Oliveira et al., 2009; Somm et al., 2008). It has been
suggested that prenatal nicotine exposure may result in
increased adiposity/body weight via alterations in the central
endocrine control of body weight homeostasis. The signals for
body weight regulation and energy balance are ultimately
integrated in the hypothalamus, which is arguably the most
important center in the brain for the regulation of appetite and
body weight homeostasis (Hillebrand et al., 2002; Kalra et al.,
1999; Wilding, 2002). Wideroe et al. (2003) suggested that the
underlying mechanism for the reported association between
maternal smoking and childhood overweight may be in-
appropriate changes in the hypothalamic regulation of energy
homeostasis resulting in increased appetite. Indeed, nicotinic
acetylcholine receptors (nAChR) are widely distributed in the
hypothalamus (Jo et al., 2002; Li et al., 2003), and Grove et al.
(2001) have shown that in utero exposure to nicotine in the
rhesus macaque can alter hypothalamic expression of both
neuropeptide Y and proopiomelanocortin (POMC) messenger
RNA (mRNA), regulators of appetite and satiety, in the
neonate. Similarly, neonatal rats treated with nicotine also have
signiﬁcantly upregulated levels of POMC mRNA in the arcuate
nucleus, an effect that was blocked by dihydro-b-erythroidine,
an a4b2 nAChR antagonist (Huang and Winzer-Serhan, 2007).
These results suggest that the nicotine-induced alterations in
body weight homeostasis may be regulated by changes in
hypothalamic control mechanisms during fetal life.
Type 2 diabetes. We have demonstrated that in rats,
nicotine exposure alone, during pregnancy and lactation,
results in endocrine and metabolic changes in the adult
offspring (i.e., 26 weeks of age) that are consistent with the
disturbed glucose metabolism that may lead to type 2 diabetes
(Holloway et al., 2005). In humans, type 2 diabetes results
from a progressive reduction in the ability of the pancreas to
produce sufﬁcient insulin to maintain normal glucose homeo-
stasis and compensate for any underlying resistance to the
action of insulin (Butler et al., 2003; Marchetti et al., 2006).
Impaired insulin secretion may be because of a reduced number
of insulin-secreting cells (i.e., beta cell mass) and/or abnormal
insulin secretion from the beta cells (i.e., beta cell function).
Insulin resistance, a reduced sensitivity to insulin action, is also
a major component of the pathophysiology of type 2 diabetes
and can be characterized by defective insulin signaling in
insulin target tissues and/or impaired insulin-stimulated
glucose transport in skeletal muscle.
In rats, fetal and neonatal exposure to nicotine adversely
affects pancreatic development and postnatal beta cell survival
and function (Bruin et al., 2007b, 2008a,b,c). Beta cell mass is
determined by a balance of beta cell size, replication,
neogenesis, and apoptosis (Bouwens and Rooman, 2005; Hill,
2005; Rhodes, 2005). We have demonstrated that fetal and
neonatal nicotine exposure caused a permanent loss of beta cell
mass beginning at birth, which was attributed to increased
levels of beta cell apoptosis and a decreased capacity for islet
cell proliferation compared with saline controls (Bruin et al.,
2007b). This is similar to humans with type 2 diabetes, in
which the primary cause of impaired beta cell mass is increased
apoptosis (Butler et al., 2003). Furthermore, Somm et al.
(2008) have assessed the effects of prenatal nicotine exposure
on beta cell neogenesis in a similar animal model. In their
study, fetal and neonatal exposure to nicotine resulted in
reduced islet size and number, as well as a reduction in beta
cell neogenesis, as determined by impaired islet gene
expression of Pdx-1, Pax-6, Nkx6.1, and insulin (Somm
et al., 2008). Regardless of the treatment protocol, nicotine-
exposed offspring subsequently developed glucose and insulin
intolerance, hyperinsulinemia, and increased body weight
during adulthood (Holloway et al., 2005; Somm et al.,
2008). Taken together, these studies show clearly that in
animals, fetal and neonatal exposure to nicotine has profound
effects on fetal and neonatal pancreatic development resulting
in abnormal glucose homeostasis in adulthood.
Our laboratory has further examined the mechanism by
which fetal and neonatal nicotine causes loss of beta cell mass
and function. We propose that nicotine binds to the nAChR on
the developing beta cell, causing an increase in the production
of intracellular reactive oxygen species (Bruin et al., 2008b).
Because the antioxidant defense system in the beta cells is
known to be relatively low compared with other cell types
(Lenzen et al., 1996; Tiedge et al., 1997), beta cells are
particularly susceptible to oxidative stress. Notably, we have
shown increased oxidative damage speciﬁcally to mitochon-
drial proteins in the pancreas of nicotine-exposed neonates
(Bruin et al., 2008b). Indeed, mitochondrial dysfunction
appears to be a central defect in beta cells following nicotine
exposure. First, loss of beta cell mass in nicotine-exposed
LONG-TERM CONSEQUENCES OF FETAL AND NEONATAL NICOTINE EXPOSURE 367neonates was attributed to increased mitochondrial-mediated
beta cell apoptosis (Bruin et al., 2008a). Second, a progressive
deterioration of mitochondrial structure and function was
observed with increasing age following cessation of nicotine
treatment at weaning (Bruin et al., 2008c). Finally, these
mitochondrial defects were associated with impaired glucose-
stimulated insulin secretion in isolated islets and reduced
insulin granule biosynthesis (Bruin et al., 2008c), both of
which likely contributed to the altered glucose homeostasis in
this animal model.
Prenatal nicotine exposure also causes impaired insulin
sensitivity in the peripheral tissues, another hallmark of type
2 diabetes. Somm et al. (2008) reported an increased glucose
response following an insulin challenge in nicotine-exposed
offspring relative to saline controls during adulthood. Further-
more, we have shown signiﬁcantly reduced insulin receptor
protein expression (Bruin et al.,2 0 0 7 a ) and uptake of
radiolabeled insulin (Labiris et al.,2 0 0 6 )i ns k e l e t a lm u s c l ea t
26 weeks of age following fetal and neonatal nicotine exposure.
Therefore, maternal nicotine exposure may cause impaired
glucose homeostasis in offspring as a result of both defective
insulin secretion (caused by impaired pancreatic beta cell mass
and function) and reduced peripheral insulin sensitivity.
Cardiovascular Outcomes
Hypertension is one of the health consequences associated
with in utero exposure to cigarette smoking in humans (Beratis
et al., 1996; Blake et al., 2000), and animal studies suggest that
this effect may be mediated via nicotine. Indeed, fetal and
neonatal nicotine exposure results in increased blood pressure
during adulthood in both the normotensive Wistar-Kyoto rat
strain (Gao et al.,2 0 0 8 ) and a spontaneously hypertensive
strain (Pausova et al., 2003). However, the mechanisms for
blood pressure elevation in the offspring of the nicotine-
exposed dams are not fully understood.
Results from other studies suggest that fetal and neonatal
exposure to nicotine in rats causes elevated blood pressure
postnatally because of endothelial dysfunction (Xiao et al.,
2007) and/or changes in renal structure or function (Mao et al.,
2009; Pausova et al., 2003). However, in our animal model,
there was no evidence of either endothelial dysfunction or
altered renal structure in the nicotine-exposed offspring at
6 months of age (Gao et al., 2008). Instead, data from these
experiments have shown that fetal and neonatal exposure to
nicotine (1) changes the composition and amount of perivas-
cular adipose tissue and (2) impairs the ability of the
perivascular adipose tissue to attenuate the contractile response
of blood vessels (Gao et al., 2005, 2008).
Because perivascular adipose tissue surrounds almost all
systemic arteries and is an important modulator of vascular
function (Gao et al., 2007; Gollasch and Dubrovska, 2004),
these data suggest that the elevated postnatal blood pressure in
nicotine-exposed offspring may be at least partly attributed to
altered perivascular adipose tissue function.
Prenatal nicotine exposure also leads to stress-induced
cardiac defects in the offspring. Nicotine-exposed rat offspring
had elevated left ventricle myocardial infarct size and de-
creased postischemic recovery of left ventricle function
following 25 min of ischemia during adulthood (Lawrence
et al., 2008). Similarly, intolerance to neonatal hypoxia has
been attributed to impaired maintenance of cardiac function
following prenatal nicotine exposure (Slotkin et al., 1997).
Control rats responded to hypoxic conditions with initial
tachycardia and a subsequent slight decline in heart rate,
whereas nicotine-exposed pups show no tachycardia and
a rapid decline in heart rate (Slotkin et al., 1997). These
effects also extended into adulthood with nicotine-exposed rats
showing a higher incidence of arrhythmia in response to stress
at 4–5 months of age compared with saline controls (Feng
et al., 2010). Taken together, animal studies demonstrate that
developmental nicotine exposure may play a key role in the
increased risk of hypertension following maternal smoking
(Beratis et al., 1996; Blake et al., 2000). Furthermore, nicotine-
induced cardiac dysfunction may also be involved in the
increased risk of SIDS in cigarette smoke–exposed neonates
(Mitchell and Milerad, 2006).
Respiratory Outcomes
Lung development. Epidemiological studies have associ-
ated maternal cigarette smoke exposure with a variety of
adverse pulmonary function outcomes in the offspring.
Maternal smoking during pregnancy doubles the risk of
wheezing and asthma in offspring up to 2 years of age
(Lannero et al., 2006) and is associated with diminished lung
function parameters in children (Gilliland et al., 2000). The risk
of the offspring developing asthma following maternal
smoking during pregnancy remains elevated as the children
reach school age, adolescence, and adulthood (Gilliland et al.,
2001; Skorge et al., 2005). In addition, maternal smoking
during pregnancy synergizes with personal smoking in later life
to increase airﬂow limitations in chronic obstructive pulmonary
disease (Upton, 2004).
Similarly, perinatal exposure to nicotine also has a profound
impact on lung development and postnatal lung function.
Because this topic has been reviewed in detail elsewhere
(Campos et al., 2009; Hafstrom et al., 2005; Maritz, 2008), we
will only highlight selected studies. For instance, nicotine can
alter airway structure and mechanics in fetal monkeys,
resulting in decreased pulmonary function parameters such as
forced expiratory volume, forced vital capacity, and expiratory
reserve volume (Sekhon et al., 1999, 2001, 2002). In addition,
nicotine impairs alveolarization in the lungs of perinatally
exposed rats (Maritz, 2002; Maritz and Thomas, 1994; Maritz
and Windvogel, 2003; Petre et al., 2008). Offspring of
nicotine-treated lambs also had abnormal postnatal breathing
patterns (Hafstrom et al., 2002a) and proximal airway
obstruction (Sandberg et al., 2004). However, the long-term
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well described. Maritz and Windvogel (2003) have followed
offspring from their studies up to postnatal day 42 and have
observed accelerated aging of the lungs, characterized by
microscopic emphysema, enlarged alveolar volume, increased
ﬂattening of alveoli with age, and decreased internal surface
area for gas exchange. Similarly, in our laboratory, nicotine
exposure resulted in altered alveolarization and reduced lung
vascularization in the neonates, suggesting that gas exchange
might be compromised. However, these changes in lung struc-
ture in neonatal life did not translate into permanent functional
changes in lung mechanics or airway responsiveness to
a methacholine challenge during adulthood (Petre et al., 2008).
Hypoxia sensing. Cigarette smoking during pregnancy is
associated with an increased risk of SIDS (Mitchell and
Milerad, 2006). Indeed, exposure to nicotine alone during
gestation in rats results in increased mortality during a hypoxic
challenge on the day after birth (Slotkin et al., 1995). As
previously discussed, this effect has been attributed, in part, to
the adverse consequences of maternal nicotine on the
maintenance of postnatal cardiac function under conditions of
ischemic stress (Lawrence et al.,2 0 0 8 ; Slotkin et al.,1 9 9 7 ). In
addition, studies in lambs have shown that prenatal nicotine
exposure alters the lung mechanical response to hypoxia
(Sandberg et al., 2007) and blunts the major cardiorespiratory
defense systems to hypoxia (i.e., heart rate and ventilatory and
arousal responses) (Hafstrom et al., 2002b). It has been
proposed that these defects may all be attributed to the deﬁcient
adrenomedullary catecholamine release observed during hyp-
oxia in nicotine-exposed neonatal rats (Slotkin et al., 1995).
Indeed, in our animal model, there is an impaired ability of
adrenomedullary chromafﬁn cells to respond to hypoxic stress
following fetal nicotine exposure (Buttigieg et al., 2008).
Nicotine treatment of primary chromafﬁn cells (isolated from
neonates) in culture blunted hypoxia-induced catecholamine
secretion (Buttigieg et al., 2009). Similarly, signiﬁcantly lower
levels of catecholamines were detected in umbilical cord blood
of smokers compared with nonsmokers (Oncken et al., 2003).
Therefore, prenatal nicotine exposure blunts the neonatal
response to hypoxia via a combination of respiratory,
cardiovascular, and adrenal chromafﬁn cell defects.
Fertility Outcomes
It has been well documented that there is a signiﬁcant
association between smoking and reduced fertility among
females (Augood et al., 1998; Greenlee et al., 2003; Hughes
and Brennan, 1996; Hull et al., 2000; Shiverick and Salaﬁa,
1999) and males (Kunzle et al., 2003; Vine, 1996).
Furthermore, cotinine (the metabolite of nicotine), cadmium
(a heavy metal in cigarette smoke), and benzo[a]pyrene (a
polyaromatic hydrocarbon in cigarette smoke) have been
detected in the follicular ﬂuid of women who smoke (Neal
et al., 2008; Younglai et al., 2002; Zenzes et al., 1995),
demonstrating that chemicals present in cigarette smoke can
accumulate in the ovary. It has been suggested that impaired
fertility in women who smoke may be the result of a combination
of impaired oocyte function and viability, decreased fertilization
rates, altered ovarian steroidogenesis, depleted ovarian reserves,
and increased chromosomal abnormalities in oocytes (Harrison
et al.,1 9 9 0 ; Klonoff-Cohen et al.,2 0 0 1 ; Ness et al.,1 9 9 9 ; Van
Voorhis et al.,1 9 9 6 ; Zenzes et al.,1 9 9 5 ).
In human populations, there is also evidence to suggest that
fetal exposure to cigarette smoke is associated with reduced
fertility during adulthood in both men and women (Jensen
et al., 1998; Sharpe and Franks, 2002; Weinberg et al., 1989).
Data from animal studies suggest that nicotine exposure may
be a critical component in the development of adverse
reproductive effects in the offspring of women who smoke.
In our animal model, nicotine exposure during fetal and
neonatal development resulted in reduced fertility, dysregula-
tion of ovarian steroidogenesis, and altered follicle dynamics in
female offspring (Holloway et al.,2 0 0 6 ). Furthermore,
developmental nicotine exposure resulted in reduced granulosa
cell proliferation, increased ovarian cell apoptosis, and de-
creased ovarian angiogenesis during adulthood compared with
saline controls (Petrik et al., 2009), an effect that may be
mediated, in part, via changes in the intra-ovarian growth
insulin-like growth factor system (Cesta et al., 2009).
The results for male offspring appear to be less profound than
the changes observed in the females. There were some transient
defects noted in the histopathology of nicotine-exposed testes
during the peripubertal period (7 weeks of age), including
increased spermatid retention, seminiferous tubule vacuolization,
leukocyte and germ cell inﬁltration into epididymal ducts, and
germcellexfoliationanddepletioninseminiferoustubules(Anzar
et al.,2 0 0 6 ). However, these structural changes were not evident
during adulthood (i.e., 26 weeks of age) and were not associated
with adverse functional outcomes at either age (Lagunov et al.,
2009). Therefore, fetal and neonatal nicotine exposure appears to
playanimportantroleintheinfertilityreportedinfemaleoffspring
of smoking mothers, but the role in male offspring remains
unclear.Thisisconsistent with a study inDanishdizygotic twins,
which reported that the female twin had reduced fecundity
following in utero cigarette smoke exposure, whereas the
fecundity of the male twin was unaffected (Jensen et al.,2 0 0 6 ).
Childhood Cancers
Prenatal exposure to tobacco smoke has been associated with
an increased risk of childhood cancers, including childhood
brain tumors and leukemia/lymphoma (Sasco and Vainio,
1999). The long-term effects of fetal and neonatal nicotine
exposure on cancer development are not well studied, but there
is certainly biological plausibility to suggest that this may be an
area of risk. Nicotine and its metabolites are known to both
initiate and promote tumor growth (Catassi et al., 2008; Martin
et al., 2009; Zheng et al., 2007). The fetus may be particularly
LONG-TERM CONSEQUENCES OF FETAL AND NEONATAL NICOTINE EXPOSURE 369vulnerable to these effects because of its reduced detoxiﬁcation
abilities (Perera et al., 2004).
Nicotine can be transformed to the carcinogenic compound,
the tobacco-speciﬁc nitrosamine, 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK). Notably, although NRT users
have reduced urinary levels of NNK metabolites compared
with smokers, nicotine from NRT was transformed to these
tobacco-speciﬁc carcinogens (Hatsukami et al.,2 0 0 4 ). NNK
and its metabolites have been detected in the urine of newborns
born to mothers who smoked cigarettes during pregnancy,
indicating placental transfer of this carcinogen (Lackmann
et al., 1999). It can be assumed that women using NRT during
pregnancy would also expose the fetus to NNK, although likely
at lower levels. Notably, NNK is a transplacental carcinogen in
the Syrian golden hamster, even at low doses (Schuller et al.,
1994). Offspring of pregnant hamsters treated with NNK
develop tumors in various different tissues, including the
respiratory tract, pancreas, liver, and adrenal glands (Correa
et al., 1990; Schuller et al., 1993, 1994). Therefore, fetal and
neonatal exposure to nicotine, via NRT or cigarette smoking,
may similarly increase the long-term risk of developing cancer,
although more research is needed to verify this hypothesis.
CONCLUSIONS
Although the human literature about the long-term effects of
NRT use during pregnancy is lacking, there is substantial
evidence from animal studies indicating that fetal and neonatal
nicotine exposure leads to widespread adverse postnatal health
consequences. For instance, in our animal model alone,
maternal nicotine exposure during gestation and lactation
caused defective metabolic (Bruin et al., 2007b, 2008a,b,c;
Holloway et al., 2005), reproductive (Anzar et al., 2006;
Holloway et al., 2006; Lagunov et al., 2009), cardiovascular
(Gao et al., 2005, 2008), pulmonary (Petre et al., 2008), and
hypoxia-sensing (Buttigieg et al., 2008, 2009) outcomes in the
offspring. Furthermore, the adverse effects of maternal nicotine
are not limited to the ﬁrst generation (F1) offspring but also
appear to affect the second generation (F2) (Holloway et al.,
2007). F2 offspring whose mothers were exposed to nicotine
during development had elevated blood pressure, increased
fasting serum insulin, and an enhanced insulin response to an
oral glucose challenge (Holloway et al., 2007). Taken together
with the vast literature on the long-term effects of de-
velopmental nicotine exposure in other animal models, these
results have signiﬁcant clinical implications and should be
considered by health associations when making policy
decisions about the safety of NRT use during pregnancy.
Overall, the evidence provided in this review overwhelmingly
indicates that nicotine should no longer be considered the
‘‘safe’’ component of cigarette smoke. In fact, many of the
adverse postnatal health outcomes associated with maternal
smoking during pregnancy may be attributable, at least in part,
to nicotine alone.
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